⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APVO News
Aptevo Therapeutics Inc
Form 8-K
sec.gov
APVO
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
accessnewswire.com
APVO
Ixinity (Medexus Pharma) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
XOMA
APVO
Form 8-K
sec.gov
APVO
eVTOL Aircraft Market worth $5.08 billion by 2035 - Exclusive Report by MarketsandMarkets™
prnewswire.com
JOBY
EH
EVEX
APVO
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
accessnewswire.com
APVO
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
accessnewswire.com
APVO
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
accessnewswire.com
APVO
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
accessnewswire.com
APVO
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
accessnewswire.com
APVO